About Us
About Us
Group Introduction Management Team Development Strategy Corporate Culture Milestones Contact Us
News
News
News
Global
Global
Global Layout Asia North America Africa Europe
Products
Products
API Preparation
R&D and Innovation
R&D and Innovation
Overview R&D Centers Development Progress Technology Platform Introduction To Key Projects
Partnership
Partnership
We Seek We Offer
Investor Relations
Investor Relations
Corporate Governance Financial Highlight Periodical Ad-hoc Investor Interaction

En

English 中文
  • About Us
    Group Introduction Management Team Development Strategy Corporate Culture Milestones Contact Us
  • News
    News
  • Global
    Global Layout Asia North America Africa Europe
  • Products
    API Preparation
  • R&D and Innovation
    Overview R&D Centers Development Progress Technology Platform Introduction To Key Projects
  • Partnership
    We Seek We Offer
  • Investor Relations
    Corporate Governance Financial Highlight Periodical Ad-hoc Investor Interaction
Ad-hoc
CURRENT LOCATION: HOME > Investor Relations > Ad-hoc

Corporate Governance

Financial Highlight

Periodical

Ad-hoc

Investor Interaction

Ad-hoc

临2021-019号(人福医药集团股份公司关于2020 年度第二期超短期融资券兑付公告)

2021.02.23

临2021-018号(人福医药集团股份公司关于琥珀酸美托洛尔缓释片获得美国 FDA 批准文号的公告)

2021.02.23

临2021-017号 (人福医药集团股份公司关于控股股东股份质押的公告)

2021.02.19

临2021-016号 (人福医药集团股份公司关于公司副总裁辞职的公告)

2021.02.09

临2021-015号 (人福医药集团股份公司关于董事减持股份计划的公告)

2021.02.09

临2021-014号(人福医药集团股份公司董事会关于为子公司提供担保的公告)

2021.02.06

临2021-013号(人福医药集团股份公司董事会关于为控股子公司提供关联担保的公告)

2021.02.06

临2021-012号(人福医药集团股份公司关于签订募集资金专户存储四方监管协议的公告)

2021.02.06

临2021-011号(人福医药集团股份公司关于签订募集资金专户存储三方监管协议的公告)

2021.02.06

临2021-010号(人福医药集团股份公司第十届董事会第十次会议决议公告)

2021.02.06

临2021-009号(人福医药集团股份公司关于发行股份购买资产并募集配套资金暨关联交易之非公开发行股票募集配套资金发行结果暨股本变动公告)

2021.02.06

临2021-008号(人福医药集团股份公司关于控股股东部分股份解除质押的公告)

2021.02.05
  •  
  • 1
  • 2
  • ...
  • 52
  • 53
  • 54
  • 55
  • 56
  • ...
  • 128
  • 129
  •  
  • CURRENT LOCATION:

    HOME > Investor Relations> Ad-hoc
    About Us
    Group Introduction
    Management Team
    Development Strategy
    Corporate Culture
    Milestones
    Contact Us
    News
    News
    Global
    Global Layout
    Asia
    North America
    Africa
    Europe
    Products
    API
    Preparation
    R&D and Innovation
    Overview
    R&D Centers
    Development Progress
    Technology Platform
    Introduction To Key Projects
    Partnership
    We Seek
    We Offer
    Investor Relations
    Corporate Governance
    Financial Highlight
    Periodical
    Ad-hoc
    Investor Interaction

    COPYRIGHT 2024 HUMANWELL GROUP ALL RIGHTS RESERVED.

    Privacy protection Legal statement
    Technical Support: Lucky xp
    Group Subsidiary GROUP SUBSIDIARY
    Yichang Humanwell Pharmaceutical Co., Ltd Hubei Gedian Humanwell Pharmaceutical Co.,Ltd. Wuhan Humanwell Pharmaceutical Co., Ltd Xinjiang Uyghur Pharmaceutical Co., Ltd. Humanwell Puke Pharmaceutical (Wuhan) Co., Ltd Yichang Sanxia Pharmaceutical Co., Ltd Epic Pharma, LLC Beijing Baron Medical Equipment Co., Ltd. Wuhan Tianrun Health Products Co., Ltd.
    QRCode
    Group Subsidiary GROUP SUBSIDIARY
    Yichang Humanwell Pharmaceutical Co., Ltd Hubei Gedian Humanwell Pharmaceutical Co.,Ltd. Wuhan Humanwell Pharmaceutical Co., Ltd Xinjiang Uyghur Pharmaceutical Co., Ltd. Humanwell Puke Pharmaceutical (Wuhan) Co., Ltd Yichang Sanxia Pharmaceutical Co., Ltd Epic Pharma, LLC Beijing Baron Medical Equipment Co., Ltd. Wuhan Tianrun Health Products Co., Ltd.
    QRCode

    COPYRIGHT 2024 HUMANWELL GROUP ALL RIGHTS RESERVED.

    Privacy protection Legal statement
    Technical Support: Lucky xp